Association study between herpes zoster reporting and mRNA COVID‐19 vaccines (BNT162b2 and mRNA‐1273)
| dc.rights.license | open | en_US |
| dc.contributor.author | PRETA, Laure-Helene | |
| dc.contributor.author | CONTEJEAN, Adrien | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | SALVO, Francesco | |
| dc.contributor.author | TRELUYER, Jean Marc | |
| dc.contributor.author | CHARLIER, Caroline | |
| dc.contributor.author | CHOUCHANA, Laurent | |
| dc.date.accessioned | 2022-06-14T15:09:27Z | |
| dc.date.available | 2022-06-14T15:09:27Z | |
| dc.date.issued | 2022-07 | |
| dc.identifier.issn | 0306-5251 | en_US |
| dc.identifier.uri | oai:crossref.org:10.1111/bcp.15280 | |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/140215 | |
| dc.description.abstractEn | Several cases of herpes zoster (HZ) following mRNA COVID-19 vaccination (BNT162b2 and mRNA-1273) have been reported, and the first epidemiological evidence suggests an increased risk. We used the worldwide pharmacovigilance database VigiBase to describe HZ cases following mRNA COVID-19 vaccination. We performed disproportionality analyses (case/non-case statistical approach) to assess the relative risk of HZ reporting in mRNA COVID-19 vaccine recipients compared to influenza vaccine recipients and according to patient age. To 30 June 2021, of 716 928 reports with mRNA COVID-19 vaccines, we found 7728 HZ cases. When compared to influenza vaccines, mRNA COVID-19 vaccines were associated with a significantly higher reporting of HZ (reporting odds ratio 1.9, 95% CI 1.8–2.1). Furthermore, we found a reduced risk of reporting HZ among under 40-year-old persons compared to older persons (reporting odds ratio 0.39, 95% CI 0.36–0.41). Mild and infrequent HZ reactions may occur shortly after mRNA COVID-19 vaccination, at higher frequency than reported with influenza vaccination, especially in patients over 40 years old. Further analyses are needed to confirm this risk. | |
| dc.language.iso | EN | en_US |
| dc.source | crossref | |
| dc.subject.en | COVID-19 | |
| dc.subject.en | Disproportionality | |
| dc.subject.en | Herpes zoster | |
| dc.subject.en | mRNA vaccines | |
| dc.subject.en | Pharmacovigilance | |
| dc.title.en | Association study between herpes zoster reporting and mRNA COVID‐19 vaccines (BNT162b2 and mRNA‐1273) | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1111/bcp.15280 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | |
| dc.identifier.pubmed | 35174524 | en_US |
| bordeaux.journal | British Journal of Clinical Pharmacology | en_US |
| bordeaux.page | 3529-3534 | en_US |
| bordeaux.volume | 88 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 7 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | dissemin | |
| hal.identifier | hal-03696617 | |
| hal.version | 1 | |
| hal.date.transferred | 2022-06-17T22:22:07Z | |
| hal.export | true | |
| workflow.import.source | dissemin | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=British%20Journal%20of%20Clinical%20Pharmacology&rft.date=2022-07&rft.volume=88&rft.issue=7&rft.spage=3529-3534&rft.epage=3529-3534&rft.eissn=0306-5251&rft.issn=0306-5251&rft.au=PRETA,%20Laure-Helene&CONTEJEAN,%20Adrien&SALVO,%20Francesco&TRELUYER,%20Jean%20Marc&CHARLIER,%20Caroline&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||